Free Access
Clinical Pharmacy Services, Pharmacy Staffing, and Hospital Mortality Rates
C. A. Bond Pharm. D., FASHP, FCCP,
Cynthia L. Raehl Pharm. D., FASHP, FCCP,
Corresponding Author
C. A. Bond Pharm. D., FASHP, FCCP
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center–Amarillo, 1300 South Coulter Street, Amarillo, TX 79106; e-mail: [email protected].Search for more papers by this authorCynthia L. Raehl Pharm. D., FASHP, FCCP
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Search for more papers by this authorC. A. Bond Pharm. D., FASHP, FCCP,
Cynthia L. Raehl Pharm. D., FASHP, FCCP,
Corresponding Author
C. A. Bond Pharm. D., FASHP, FCCP
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center–Amarillo, 1300 South Coulter Street, Amarillo, TX 79106; e-mail: [email protected].Search for more papers by this authorCynthia L. Raehl Pharm. D., FASHP, FCCP
Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas.
Search for more papers by this authorAbstract
Objective: To determine if hospital-based clinical pharmacy services and pharmacy staffing continue to be associated with mortality rates.
Methods: A database was constructed from 1998 MedPAR, American Hospital Association's Annual Survey of Hospitals, and National Clinical Pharmacy Services databases, consisting of data from 2,836,991 patients in 885 hospitals. Data from hospitals that had 14 clinical pharmacy services were compared with data from hospitals that did not have these services; levels of hospital pharmacist staffing were also compared. A multiple regression analysis, controlling for severity of illness, was used.
Results: Seven clinical pharmacy services were associated with reduced mortality rates: pharmacist-provided drug use evaluation (4491 reduced deaths, p=0.016), pharmacist-provided in-service education (10,660 reduced deaths, p=0.037), pharmacist-provided adverse drug reaction management (14,518 reduced deaths, p=0.012), pharmacist-provided drug protocol management (18,401 reduced deaths, p=0.017), pharmacist participation on the cardiopulmonary resuscitation team (12,880 reduced deaths, p=0.009), pharmacist participation on medical rounds (11,093 reduced deaths, p=0.021), and pharmacist-provided admission drug histories (3988 reduced deaths, p=0.001). Two staffing variables, number of pharmacy administrators/100 occupied beds (p=0.037) and number of clinical pharmacists/100 occupied beds (p=0.023), were also associated with reduced mortality rates.
Conclusion: The number of clinical pharmacy services and staffing variables associated with reduced mortality rates increased from two in 1989 to nine in 1998. The impact of clinical pharmacy on mortality rates mandates consideration of a core set of clinical pharmacy services to be offered in United States hospitals. These results have important implications for health care in general, as well as for our profession and discipline.
References
- 1 Bond CA, Raehl CL, Pitterle ME, Franke T. Health care professional staffing, hospital characteristics, and hospital mortality rates. Pharmacotherapy 1999; 19: 130–8.
- 2 Bond CA, Raehl CL, Pitterle ME. Staffing and the cost of clinical and hospital pharmacy services in United States hospitals. Pharmacotherapy 1999; 19: 767–81.
- 3 Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy 2001; 21: 129–41.
- 4 Bjornson DC, Hiner WO, Potyk RP, et al. Effect of pharmacist on health care outcomes in hospitalized patients. Am J Hosp Pharm 1993; 50: 1875–84.
- 5 Boyko WL, Yurkowski PJ, Ivey M, et al. Pharmacist influence on economic and morbidity outcomes in a tertiary care teaching hospital. Am J Health-Syst Pharm 1997; 54: 1591–5.
- 6 Pitterle ME, Bond CA, Raehl CL, Franke T. Hospital and pharmacy characteristics associated with mortality rates in United States hospitals. Pharmacotherapy 1994; 14: 620–30.
- 7 Carter JH, Mills AC, Homan SM, et al. Correlating the quality of care with nursing resources and patient parameters: a longitudinal study. NLN Publ 1987(20–2191): 331–45.
- 8 Kelly JV, Hellinger FJ. Physician and hospital factors associated with mortality of surgical patients. Med Care 1986; 24: 785–800.
- 9 Rhee SO. Factors determining the quality of physician performance in patient care. Med Care 1976; 14: 733–50.
- 10 Shortell SM, Hughes EFX. The effects of regulation, competition, and ownership on mortality rates among hospital inpatients. N Engl J Med 1988; 318: 1100–7.
- 11 Dubois RW, Brooks RH, Rodgers WH. Adjusted hospital death rates: a potential screen for quality of medical care. Am J Public Health 1987; 77: 1162–7.
- 12 Krakauer H, Bailey RC, Skellan KJ, Stewart JD, Hartz AJ. Evaluation of the HCFA model for the analysis of mortality following hospitalization. Health Serv Res 1992; 27: 317–35.
- 13 Hartz AJ, Gottlieb M, Kuhn ER, Rimm A. National validation study of Medicare mortality studies (project # 1247-M). Technical report to the Health Standards and Quality Review Bureau, Washington, D.C.: U.S. Government Print Office, 1989.
- 14 Hartz AJ, Krakauer H, Kuhn EM, et al. Hospital characteristics and mortality rates. N Engl J Med 1989; 321: 1720–5.
- 15 Brook RH, Cleary PD. Measuring quality of care: part two of six. N Engl J Med 1996; 335: 966–70.
- 16 Keeler EB, Rubenstein LV, Kahn KL, et al. Hospital characteristics and quality of care. JAMA 1992; 268: 1709–14.
- 17 Mayer T, Cates RJ. Service excellence in health care. JAMA 1999; 282: 1281–3.
- 18 Williams SC, Schmaltz SP, Morton DJ, Koss RG, Loeb JM. Quality of care in U.S. hospitals reflected by standardized measures, 2002–2004. N Engl J Med 2005; 353: 255–64.
- 19 Jha AK, Zhonghe LMA, Orqv EJ, Epstein AM. Care in US hospitals: the quality alliance program. N Engl J Med 2005; 353: 265–74.
- 20 Green J, Wintfield N, Sharkey P, Passman LJ. The importance of severity of illness measures in assessing hospital mortality. JAMA. 1990; 262: 241–6.
- 21 Green J, Passman LJ, Wintfield N. Analyzing hospital mortality: the consequences of diversity in patient mix. JAMA 1991; 265: 1849–53.
- 22 U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Expanded modified Medicare provider analysis and review (MedPAR-Hospital [National] FY 1998) on IBM 3480 tape cartridges. Baltimore, MD: Department of Health and Human Services, 1998.
- 23 Raehl CL, Bond CA. 1998 national clinical pharmacy services study. Pharmacotherapy 2000; 20: 436–60.
- 24 Raehl CL, Bond CA, Pitterle ME. 1995 national clinical pharmacy services study. Pharmacotherapy 1998; 18: 302–26.
- 25 Raehl CL, Bond CA, Pitterle ME. Hospital pharmacy services in the Great Lakes region. Am J Hosp Pharm 1990; 49: 1283–303.
- 26 Raehl CL, Bond CA, Pitterle ME. Pharmaceutical services in U.S. hospitals in 1989. Am J Hosp Pharm 1992; 49: 323–46.
- 27 Bond CA, Raehl CL, Pitterle ME. 1992 national clinical pharmacy services study. Pharmacotherapy 1994; 14: 282–304.
- 28 American Hospital Association. Annual survey of hospitals on diskettes, 1998. Chicago, IL: American Hospital Association, 1999.
- 29 Wampole BE, Freund RD. Use of multiple regression in counseling psychology research: a flexible data analytic strategy. J Counsel Psychol 1987; 34: 372–82.
- 30 Pedhazur EJ. Multiple regression in behavioral research: explanation and prediction, 2nd ed. New York: Harcourt Brace Jovanonich, 1982.
- 31 Greenfield S, Aronow HU, Elashoff RM, Watanaabe D. Flaws in mortality data: hazards of ignoring comorbid disease. JAMA 1988; 260: 2253–355.
- 32 Kenlel P. Hospitals balk at mortality report results. Modern Healthcare January 1, 1988: 5–6.
- 33 Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996–2000. Pharmacotherapy 2003; 23: 113–32.
- 34 Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267–70.
- 35 Schumock GT, Meek PD, Ploetz PA, et al. Economic evaluation of clinical pharmacy services—1988-1995. Pharmacotherapy 1996; 16: 1188–208.
- 36 Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure team. Arch Intern Med 1999; 159: 1939–45.
- 37 Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285: 2114–20.
- 38 Clapham CE, Hepler CE, Reinders TP, et al. Economic consequences of two drug-use control systems in a teaching hospital. Am J Hosp Pharm 1988; 45: 2329–40.
- 39 Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy 1996; 16: 708–14.
- 40 McKenney JM, Wasserman AH. Effect of advanced pharmaceutical services on the incidence of adverse drug reactions. Am J Hosp Pharm 1979; 36: 1691–7.
- 41 Kaboli PJ, Hoth AB, McClimon BJ, Schinipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med 2006; 166: 955–64.
- 42 Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacist staffing, and drug costs in United States hospitals. Pharmacotherapy 1999; 19: 1354–62.
- 43 Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. Pharmacotherapy 2000; 20: 609–21.
- 44 Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy 2002; 22: 134–47.
- 45 Bond CA, Raehl CL, Franke T. Medication errors in United States hospitals. Pharmacotherapy 2001; 21: 1023–36.
- 46 Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy 2004; 24: 953–63.
- 47 Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist provided aminoglycoside or vancomycin management in hospitalized Medicare patients. Am J Health-Syst Pharm 2005; 62: 1596–605.
- 48 Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals. Pharmacotherapy 2006; 26: 735–47.
- 49 Bond CA, Monson R. Sustained improvement in drug documentation, compliance, and disease control: a four-year ambulatory care model. Arch Intern Med 1984; 144: 1159–62.
- 50 Monson RA, Bond CA, Schuna A. Role of the clinical pharmacist in improving outpatient drug therapy. Arch Intern Med 1981; 141: 1441–4.
- 51 Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy 2004; 24: 427–40.
- 52 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients, JAMA 1998; 279: 1200–5.
- 53 Miller RR. Boston collaborative drug surveillance program. Arch Intern Med 1974; 134: 219–24.
- 54 Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329: 15–19.
- 55 Hammond RW, Schwartz AH, Campbell MJ, et al, for the American College of Clinical Pharmacy. Collaborative drug therapy management by pharmacists—2003. Pharmacotherapy 2003; 23: 1210–25.
- 56 Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed antiepileptic drug therapy. Pharmacotherapy 2006; 26: 1369–78.
- 57 Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med 1995; 155: 1949–56.
- 58 Bobb A, Gleason K, Husch M, et al. The epidemiology of prescribing errors. Arch Intern Med 2004; 164: 785–92.
- 59 Lessard S, DeYoung, Vazzna N.. Medication discrepancies affecting senior patients at hospital admission. Am J Health-Syst Pharm 2006; 63: 740–3.
- 60 Joint Commission on Accreditation of Healthcare Organizations. Joint Commission 2005 national patient safety goals. Available from http:www.jointcommission.orgNRrdonlyresCA814047-805D-4143-AD3C-0C1944C49E75005_hap_npsg.pdf. Accessed April 25, 2006.
- 61 University of Kentucky College of Pharmacy. Drug information centers close. Available from http:www.mc.uky.edupharmacydic. Accessed April 26, 2006.
- 62 Joint Commission on Accreditation of Healthcare Organizations. Evolution of performance measures at the Joint Commission, Feb. 8, 2006. Available from http:www.jointcommission.orgNRrdonlyres333A4688-7E50-41CF-B63D-EE0278D0C6530EvolutionofPM.pdf. Accessed April 26, 2006.
- 63 American Association of Colleges of Pharmacy. Student applications, enrollments, and degrees confirmed. Available from http:www.aacp.orgIDVEnrollmentenrollments04.htm. Accessed May 11, 2006.
- 64 Kelly WN. Potential risks and prevention, part 1: fatal adverse drug events. Am J Health-Syst Pharm 2001; 58: 1317–24.
- 65 Kelly WN. Potential risks and prevention, part 4: reports of significant adverse drug events. Am J Health-Syst Pharm 2001; 58: 1406–12.
Citing Literature
